| Revenue growth | 19.5% YoY |
|---|---|
| Margins | EBITDA margin expanded 530 bps YoY to 21.6% |
| Demand visibility | Strong, especially in Formulations (33% Q1 YoY growth) |
| Management confidence | High; citing integration success and well-defined growth strategy |
Growth
Q1 FY27 Revenue at ₹9,464 Mn (+19.5% YoY); EBITDA at ₹2,047 Mn (+59.2% YoY); PAT at ₹793 Mn (+114.9% YoY).
Outlook
Acquisition of Bio For Life (Italy) to drive companion animal segment; strong R&D pipeline with 85+ APIs and 105+ FDFs.
Risks
Higher ESOP costs due to amalgamation and hyperinflation adjustments in Turkey (Ind AS 29).
Last quarter's promises, checked
Delivered
- Guided 15% annual growth → delivered 19.5% YoY (= BEAT)
- Guided EBITDA run rate of INR 800 Cr → delivered INR 2,047 Mn for Q1 (= BEAT)
- Guided tax rate ~27% → delivered 27.8% (= BEAT)
Partly delivered
- Guided double-digit API growth → delivered 4% YoY in Q1 (= MISS)
Investor Presentation filed with NSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹244.35
- Market cap
- ₹10,791 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 63.0×Sector 50.4×
- Promoter holding
- 61.31%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 1,107,309 ESOP shares at exercise prices of ₹86 and ₹101. Paid-up capital rose to ₹88.33 Crore post-allotment.
Viyash Scientific Merger & Restructuring
Viyash Scientific Limited announced receipt of Italian regulatory approval for its subsidiary Alivira Animal Health's acquisition of BioForLife Italia S.r.l. The transaction completion timeline is extended.
Viyash Scientific Acquisition
Viyash Scientific Limited received Italian regulatory approval for its proposed 100% acquisition of BioForLife Italia S.r.l., with the completion timeline now extended by two months.
Viyash Scientific Employee Stock Options
Viyash Scientific Limited allotted 6,12,773 equity shares following the exercise of options under its ESOP 2020 and 2026 schemes. The company's paid-up capital increased to Rs. 88.10 Crore.
Viyash Scientific Investor Presentation: Key Takeaways
Viyash Scientific delivered strong Q1 FY27 results with 19.5% revenue growth and significant margin expansion. Integration is complete, and the company is now virtually debt-free, pivoting toward oncology and companion animal health.
- Call
- Guides 18% growth
Viyash Scientific Earnings Call Transcript: Key Takeaways
Viyash reports a robust Q1FY27 with 20% revenue growth and significantly expanded EBITDA margins at 21.6%. The company is essentially net-debt free following successful integration and is pivoting toward high-potent oncology products.
- Call
- Guides 18% growth